uniQure’s chief medical officer sells shares worth $13,891

AMSTERDAM—Walid Abi-Saab, the Chief Medical (TASE:BLWV) Officer of uniQure N.V. (NASDAQ:QURE), recently executed a sale of company shares valued at $13,891. The transaction comes as the stock trades at $12.09, showing a remarkable 118% surge over the past six months despite the company’s weak financial health score according to InvestingPro analysis. According to the SEC filing dated March 5, 2025, Abi-Saab sold 1,350 ordinary shares on March 4 at a weighted average price of $10.29 per share. The sale was conducted to cover estimated withholding taxes upon the vesting of restricted share units, as specified in the relevant Restricted Share Unit Agreement. With a current market capitalization of $650 million and trading near InvestingPro’s Fair Value estimate, the stock exhibits high volatility - one of 12 key insights available to Pro subscribers.

In addition to the sale, Abi-Saab acquired 38,000 ordinary shares on March 3 as part of a restricted share unit grant under the company’s 2014 Share Incentive Plan. These shares were acquired at no cost, as they represent the contingent right to receive ordinary shares, vesting in equal annual installments over three years.

Furthermore, Abi-Saab was granted stock options to purchase 66,000 ordinary shares at an exercise price of $10.90 per share. These stock options will vest over a period, commencing with 25% on the first anniversary of the grant date and continuing quarterly thereafter, contingent upon his ongoing relationship with the company.

Following these transactions, Abi-Saab holds 151,903 ordinary shares directly.

In other recent news, uniQure announced the pricing of its public offering, setting the share price at $17 to raise approximately $75 million before deductions. The offering includes 4,411,764 ordinary shares, with an option for underwriters to purchase additional shares, and is expected to close in early January 2025. H.C. Wainwright reaffirmed its Buy rating for uniQure with a $70 price target, citing optimism about the company’s gene therapy programs, particularly AMT-130 for Huntington’s disease. The firm highlighted the potential for accelerated approval pathways and the significance of upcoming regulatory milestones. Meanwhile, uniQure has completed enrollment for the first cohort in its Phase I/IIa trial of AMT-191 for Fabry disease, with no significant safety concerns reported. The Independent (LON:IOG) Data Monitoring Committee has recommended proceeding with the second cohort, set to begin in the first quarter of 2025. Additionally, CSL (OTC:CSLLY) Behring confirmed the long-term efficacy of HEMGENIX, a hemophilia B treatment initially developed by uniQure, through a four-year study. The study demonstrated sustained efficacy and safety, supporting the treatment’s use in adults with hemophilia B.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.